EMA Authorised: Biktarvy (bictegravir;emtricitabine;tenofovir alafenamide;fumarate) — Gilead Sciences Ireland UC

View source ↗

Summary

The EMA has authorized Biktarvy for HIV infections, with Gilead Sciences Ireland UC as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Gilead Sciences Ireland UC. Decision date: 12/12/2025